董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Abraham Sartani | 男 | Director | 78 | 未披露 | 0.29 | 2026-03-26 |
| Yoseph Bornstein | 男 | Director | 67 | 未披露 | 未持股 | 2026-03-26 |
| Ilan Tamir | 男 | Director | 67 | 未披露 | 未持股 | 2026-03-26 |
| Pnina Fishman | 女 | Executive Chairman of the Board, Chief Scientific Officer | 77 | 55.70万美元 | 0.64 | 2026-03-26 |
| Guy Regev | 男 | Director | 55 | 6.00万美元 | 0.29 | 2026-03-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sari Fishman | 女 | VP of Business Development | 53 | 38.90万美元 | 0.39 | 2026-03-26 |
| Motti Farbstein | 男 | Chief Executive Officer, Chief Financial Officer and Chief Operating Officer | 62 | 65.00万美元 | 0.50 | 2026-03-26 |
董事简历
中英对照 | 中文 | 英文- Abraham Sartani
-
Abraham Sartani，2001年以来，他一直任职我们的董事会。他在制药行业拥有30年以上的经验，目前担任制药和医疗设备公司的顾问。他是多家科学管理协会的成员，也是泌尿外科、疼痛治疗和高血压领域的大量出版物和专利的作者或合著者。他目前也任职于Akkadeas Pharma Srl公司的董事会，是联席创始合伙人。从1985年到2008年，他曾担任Recordati公司（欧洲专业制药公司）的研发和许可副总裁。加入Recordati公司之前，他曾任职Farmitalia-Carlo Erba公司，担任多种职务，包括欧洲医疗董事（从1980年到1985年）。
Abraham Sartani has served on Board of Directors since 2001. Dr. Sartani has over 30 years of experience in the pharmaceuticals indtry and currently acts as a consultant to pharmaceutical and medical device companies. Dr. Sartani is a member of a number of scientific and management societies and the author or co author of numero publications and patents in the urology, pain treatment and hypertension fields. Dr. Sartani previoly served on the Board of Directors of Akkadeas Pharma Srl (formerly Arkadia Pharma) and was a co founder. From 1985 until 2008, Dr. Sartani was the Vice President of R&D and Licensing and Group coordinator of B&D of Recordati, a European specialty pharmaceutical company. Prior to joining Recordati, from 1980 until 1985, Dr. Sartani was employed at Farmitalia Carlo Erba, serving in a number of capacities, including as the Medical Director for Europe. Currently, Dr. Sartani is a member of the board of directors of BLV Pharma Group Srl, a privately owned Italian food supplements company. - Abraham Sartani，2001年以来，他一直任职我们的董事会。他在制药行业拥有30年以上的经验，目前担任制药和医疗设备公司的顾问。他是多家科学管理协会的成员，也是泌尿外科、疼痛治疗和高血压领域的大量出版物和专利的作者或合著者。他目前也任职于Akkadeas Pharma Srl公司的董事会，是联席创始合伙人。从1985年到2008年，他曾担任Recordati公司（欧洲专业制药公司）的研发和许可副总裁。加入Recordati公司之前，他曾任职Farmitalia-Carlo Erba公司，担任多种职务，包括欧洲医疗董事（从1980年到1985年）。
- Abraham Sartani has served on Board of Directors since 2001. Dr. Sartani has over 30 years of experience in the pharmaceuticals indtry and currently acts as a consultant to pharmaceutical and medical device companies. Dr. Sartani is a member of a number of scientific and management societies and the author or co author of numero publications and patents in the urology, pain treatment and hypertension fields. Dr. Sartani previoly served on the Board of Directors of Akkadeas Pharma Srl (formerly Arkadia Pharma) and was a co founder. From 1985 until 2008, Dr. Sartani was the Vice President of R&D and Licensing and Group coordinator of B&D of Recordati, a European specialty pharmaceutical company. Prior to joining Recordati, from 1980 until 1985, Dr. Sartani was employed at Farmitalia Carlo Erba, serving in a number of capacities, including as the Medical Director for Europe. Currently, Dr. Sartani is a member of the board of directors of BLV Pharma Group Srl, a privately owned Italian food supplements company.
- Yoseph Bornstein
-
Yoseph Bornstein，在合并后成为公司董事。Bornstein先生是Microbot Israel的联合创始人，并自Microbot Israel于2010年11月成立以来一直担任董事会成员。Bornstein先生于2000年10月创立了生命科学控股集团Shizim Ltd.，并自那时起担任其总裁。Bornstein自2002年1月起担任GCP Clinical Studies Ltd.（以色列一家临床研究服务和教育项目供应商）董事长。他是Biotis Ltd.（生物制药行业的服务公司）的主席（2000年6月以来）。此外，他是Dolphin Medical Ltd.（医疗器械行业的服务公司）的主席（2012年4月以来），以及ASIS Enterprises B.B.G.Ltd.（业务发展公司，专注于创造以色列和日本实体之间的业务联系）的主席（2007年8月以来）。Bornstein先生是XACT Robotics Ltd.的联合创始人和董事，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序中开发机器人针头转向的新型平台技术，并且是Shizimxl Innovation Center的创始人。1992年10月，Bornstein先生创立Pharmateam Ltd.，这是一家以色列公司，专门代表国际制药公司，于2000年被出售。Bornstein先生还是多家其他私人持有的生命科学公司的创始人。Bornstein从2002年9月到2005年2月担任United States-Israel Science&Technology Commission the“；USISTF”；生物技术委员会主席，从2002年9月到2005年2月担任USISTF顾问。他也是ILSI-Israel Life Science Industry Organization（并入IATI）和ITTN-Israel Tech Transfer Organization的创始人。
Yoseph Bornstein,became a director of the Company following the Merger. Mr. Bornstein is a co-founder of Microbot Israel and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. Mr. Bornstein founded Shizim Ltd., a life science holding group in October 2000 and has served as its CEO and director since then. Mr. Bornstein is the Chairman of, and through Shizim owns a stake in: GCP Clinical Studies Ltd., a provider of clinical research services and educational programs in Israel since January 2002; Biotis Ltd., a service company for the bio-pharmaceutical industry, since June 2000; Dolphin Medical Ltd., which supplies the medical device industry, since April 2012, and LSA - Life Science Accelerator Ltd., since 2000. He is the Chairman of ASIS Enterprises B.B.G. Ltd., a business development company focusing on creating business ties between Israeli and Japanese entities, since August 2007. Mr. Bornstein is a co-founder and director of XACT Robotics, which is developing a novel platform technology for robotic needle steering in minimally invasive interventional procedures. In October 1992, Mr. Bornstein founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in 2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein served as the Biotechnology Committee Chairman of the United States-Israel Science & Technology Commission (the "USISTC") from September 2002 to February 2005 as well as a consultant for USISTC from September 2002 to February 2005. He is also the founder of ILSI-Israel Life Science Industry Organization (who was integrated into IATI) and ITTN-Israel Tech Transfer Organization. He founded in July 2014 ShizimXL Ltd., an international medical device innovation center, and founded in January 2020 ShizimVS Ltd., a digital health innovation center. Mr. Bornstein is an external director in Can-fite BioPharma Ltd. (Nasdaq:CANF). - Yoseph Bornstein，在合并后成为公司董事。Bornstein先生是Microbot Israel的联合创始人，并自Microbot Israel于2010年11月成立以来一直担任董事会成员。Bornstein先生于2000年10月创立了生命科学控股集团Shizim Ltd.，并自那时起担任其总裁。Bornstein自2002年1月起担任GCP Clinical Studies Ltd.（以色列一家临床研究服务和教育项目供应商）董事长。他是Biotis Ltd.（生物制药行业的服务公司）的主席（2000年6月以来）。此外，他是Dolphin Medical Ltd.（医疗器械行业的服务公司）的主席（2012年4月以来），以及ASIS Enterprises B.B.G.Ltd.（业务发展公司，专注于创造以色列和日本实体之间的业务联系）的主席（2007年8月以来）。Bornstein先生是XACT Robotics Ltd.的联合创始人和董事，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序中开发机器人针头转向的新型平台技术，并且是Shizimxl Innovation Center的创始人。1992年10月，Bornstein先生创立Pharmateam Ltd.，这是一家以色列公司，专门代表国际制药公司，于2000年被出售。Bornstein先生还是多家其他私人持有的生命科学公司的创始人。Bornstein从2002年9月到2005年2月担任United States-Israel Science&Technology Commission the“；USISTF”；生物技术委员会主席，从2002年9月到2005年2月担任USISTF顾问。他也是ILSI-Israel Life Science Industry Organization（并入IATI）和ITTN-Israel Tech Transfer Organization的创始人。
- Yoseph Bornstein,became a director of the Company following the Merger. Mr. Bornstein is a co-founder of Microbot Israel and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. Mr. Bornstein founded Shizim Ltd., a life science holding group in October 2000 and has served as its CEO and director since then. Mr. Bornstein is the Chairman of, and through Shizim owns a stake in: GCP Clinical Studies Ltd., a provider of clinical research services and educational programs in Israel since January 2002; Biotis Ltd., a service company for the bio-pharmaceutical industry, since June 2000; Dolphin Medical Ltd., which supplies the medical device industry, since April 2012, and LSA - Life Science Accelerator Ltd., since 2000. He is the Chairman of ASIS Enterprises B.B.G. Ltd., a business development company focusing on creating business ties between Israeli and Japanese entities, since August 2007. Mr. Bornstein is a co-founder and director of XACT Robotics, which is developing a novel platform technology for robotic needle steering in minimally invasive interventional procedures. In October 1992, Mr. Bornstein founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in 2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein served as the Biotechnology Committee Chairman of the United States-Israel Science & Technology Commission (the "USISTC") from September 2002 to February 2005 as well as a consultant for USISTC from September 2002 to February 2005. He is also the founder of ILSI-Israel Life Science Industry Organization (who was integrated into IATI) and ITTN-Israel Tech Transfer Organization. He founded in July 2014 ShizimXL Ltd., an international medical device innovation center, and founded in January 2020 ShizimVS Ltd., a digital health innovation center. Mr. Bornstein is an external director in Can-fite BioPharma Ltd. (Nasdaq:CANF).
- Ilan Tamir
-
Ilan Tamir在全球科技、医疗保健和资本市场组织领域拥有超过25年的领导经验。他最近于2026年3月加入董事会。Tamir先生目前是Serverfarm Israel Infrastructure Ltd.的首席财务官，负责监督公司的财务和运营业绩。Previoly，Tamir先生是Behalf Ltd.的首席财务官，在那里他被任命领导该公司的结构性破产，包括关闭在美国和以色列的业务、资产变现、数百万美元的贷款偿还以及最终的股东分配。在此之前，他曾担任Matomy Media Group（LSE/TASE）的首席运营官和首席财务官，指导公司完成高度复杂的多利益相关者重组、资产剥离和全面和解协议。在其职业生涯的早期，Tamir先生担任过高级职务，包括Kryon Systems的临时首席财务官、BRM Capital的首席财务官以及Logal Software（NASDAQ：SMPLF）的首席财务官。他还共同创立、领导并担任国际医疗服务公司iMER的董事会成员，该公司帮助患者访问全球顶级学术医疗中心。Tamir先生拥有Technion – Israel Institute of Technology的计算机科学学士学位和特拉维夫大学的MBA学位。
Ilan Tamir has over 25 years of leadership experience across global technology, healthcare, and capital markets organizations. He recently joined Board of Directors in March 2026. Mr. Tamir is currently the Chief Financial Officer at Serverfarm Israel Infrastructure Ltd. where he oversees financial and operational performance for the company. Previoly, Mr. Tamir was CFO of Behalf Ltd., where he was appointed to lead the company's structured wind down, including the closure of operations in the U.S. and Israel, asset realization, multi million dollar loan repayments, and final shareholder distributions. Before that, he served as COO and CFO of Matomy Media Group (LSE/TASE), guiding the company through a highly complex multi stakeholder restructuring, asset divestitures, and comprehensive settlement agreements. Earlier in his career, Mr. Tamir held senior roles including Interim CFO of Kryon Systems, CFO of BRM Capital, and CFO of Logal Software (NASDAQ: SMPLF). He also co founded, led, and served on the Board of iMER, an international medical services firm that helped patients access top academic medical centers worldwide. Mr. Tamir holds a B.Sc. in Computer Science from the Technion – Israel Institute of Technology and an MBA from Tel Aviv University. - Ilan Tamir在全球科技、医疗保健和资本市场组织领域拥有超过25年的领导经验。他最近于2026年3月加入董事会。Tamir先生目前是Serverfarm Israel Infrastructure Ltd.的首席财务官，负责监督公司的财务和运营业绩。Previoly，Tamir先生是Behalf Ltd.的首席财务官，在那里他被任命领导该公司的结构性破产，包括关闭在美国和以色列的业务、资产变现、数百万美元的贷款偿还以及最终的股东分配。在此之前，他曾担任Matomy Media Group（LSE/TASE）的首席运营官和首席财务官，指导公司完成高度复杂的多利益相关者重组、资产剥离和全面和解协议。在其职业生涯的早期，Tamir先生担任过高级职务，包括Kryon Systems的临时首席财务官、BRM Capital的首席财务官以及Logal Software（NASDAQ：SMPLF）的首席财务官。他还共同创立、领导并担任国际医疗服务公司iMER的董事会成员，该公司帮助患者访问全球顶级学术医疗中心。Tamir先生拥有Technion – Israel Institute of Technology的计算机科学学士学位和特拉维夫大学的MBA学位。
- Ilan Tamir has over 25 years of leadership experience across global technology, healthcare, and capital markets organizations. He recently joined Board of Directors in March 2026. Mr. Tamir is currently the Chief Financial Officer at Serverfarm Israel Infrastructure Ltd. where he oversees financial and operational performance for the company. Previoly, Mr. Tamir was CFO of Behalf Ltd., where he was appointed to lead the company's structured wind down, including the closure of operations in the U.S. and Israel, asset realization, multi million dollar loan repayments, and final shareholder distributions. Before that, he served as COO and CFO of Matomy Media Group (LSE/TASE), guiding the company through a highly complex multi stakeholder restructuring, asset divestitures, and comprehensive settlement agreements. Earlier in his career, Mr. Tamir held senior roles including Interim CFO of Kryon Systems, CFO of BRM Capital, and CFO of Logal Software (NASDAQ: SMPLF). He also co founded, led, and served on the Board of iMER, an international medical services firm that helped patients access top academic medical centers worldwide. Mr. Tamir holds a B.Sc. in Computer Science from the Technion – Israel Institute of Technology and an MBA from Tel Aviv University.
- Pnina Fishman
-
Pnina Fishman 于2005年9月共同创立 Can-Fite 并担任首席执行官及董事会成员。Fishman 博士是 Can-Fite 的科学创始人，此前曾担任生命科学教授，并在以色列 Rabin 医疗中心的 Felsenstein 医学研究所领导临床与肿瘤免疫学实验室。Fishman 博士已撰写或合著超过150篇学术论文，并在多次重要科学会议上展示了其研究成果。她过往的管理经验包括在 Mor Research Application 担任首席执行官长达七年，该公司是以色列最大医疗服务机构 Clalit Health Services 的技术转移部门，也是以色列首家临床研究组织。Fishman 博士目前还担任 F.D Consulting Ltd.、Ultratrend Ltd. 和 Eye-Fite Ltd. 的董事会成员。Fishman 博士拥有以色列 Ramat Gan 的 Bar Ilan University 免疫学博士学位。
Pnina Fishman co-founded Can-Fite and has served as Chief Executive Officer and served on Board of Directors since September 2005. Dr. Fishman is the scientific founder of Can-Fite and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center, Israel. Dr. Fishman has authored or co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her past managerial experience included seven years as Chief Executive Officer of Mor Research Application, the technology transfer arm of Clalit Health Services, the largest healthcare provider in Israel. Mor Research Application was also the first clinical research organization in Israel. Dr. Fishman currently also serves as a member of the Board of Directors of F.D Consulting Ltd., Ultratrend Ltd., and Eye-Fite Ltd. Dr. Fishman holds a Ph.D. in Immunology from the Bar Ilan University in Ramat Gan, Israel. - Pnina Fishman 于2005年9月共同创立 Can-Fite 并担任首席执行官及董事会成员。Fishman 博士是 Can-Fite 的科学创始人，此前曾担任生命科学教授，并在以色列 Rabin 医疗中心的 Felsenstein 医学研究所领导临床与肿瘤免疫学实验室。Fishman 博士已撰写或合著超过150篇学术论文，并在多次重要科学会议上展示了其研究成果。她过往的管理经验包括在 Mor Research Application 担任首席执行官长达七年，该公司是以色列最大医疗服务机构 Clalit Health Services 的技术转移部门，也是以色列首家临床研究组织。Fishman 博士目前还担任 F.D Consulting Ltd.、Ultratrend Ltd. 和 Eye-Fite Ltd. 的董事会成员。Fishman 博士拥有以色列 Ramat Gan 的 Bar Ilan University 免疫学博士学位。
- Pnina Fishman co-founded Can-Fite and has served as Chief Executive Officer and served on Board of Directors since September 2005. Dr. Fishman is the scientific founder of Can-Fite and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center, Israel. Dr. Fishman has authored or co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her past managerial experience included seven years as Chief Executive Officer of Mor Research Application, the technology transfer arm of Clalit Health Services, the largest healthcare provider in Israel. Mor Research Application was also the first clinical research organization in Israel. Dr. Fishman currently also serves as a member of the Board of Directors of F.D Consulting Ltd., Ultratrend Ltd., and Eye-Fite Ltd. Dr. Fishman holds a Ph.D. in Immunology from the Bar Ilan University in Ramat Gan, Israel.
- Guy Regev
-
Guy Regev在商业企业的会计，财务管理，主管部门和管理部门有超过12年的任职经历。他自2011年7月起一直在我们公司的董事会任职，并自2014年2月起，一直是我们公司审计委员会和薪酬委员会的成员。自2011年11月起，Regev先生还一直是OphthaliX的一名董事。Regev先生目前是Gaon Holdings Ltd.（一家以色列上市贸易公司，主要在自来水清洁，财务服务和零售贸易三个方面运营）的首席执行官。Regev先生目前还是Middle East Tube Company Ltd（一家以色列上市贸易公司，从事钢管制造和电镀服务）的首席执行官。另外，Regev先生还是Shaked Global Group Ltd（一家为环保关联和科技公司提供资本增值服务的私营股权公司，或称为Shaked公司）的首席执行官。2008年初，Regev先生加入了Shaked并在2014年4月离职。2011年11月以来，Regev先生还一直是OphthaliX公司的一名董事。在加入Shaked之前，2001年到2008年期间，Regev先生曾是HCH（以色列最大的基础设施公司）商业业务部的副主管。他在HCH公司的负责各个业务单元的巩固和财务复苏。在此之前，Regev先生曾在Blue-Green Ltd.（HCH的环境服务子公司）担任许多角色，包括首席财务官和之后的首席执行官。1999年到2001年期间，Regev先生曾是以色列Deloitte & Touche公司的经理。Regev先生拥有Law Israel的法学学士学位，是一位有证律师以及自1999年起成为一名注册会计师。Regev先生现在还是The Green Way Ltd, Shtang Construction 和Engineering Ltd, R.I.B.E. Consulting & Investment Ltd., Shaked Group Ltd, Aqua Investments Ltd, Middle East Tube Company Ltd, Middle East Tube - Industries 2001 Ltd, Middle East Tubes - Galvanizing -1994 Ltd, I-Solar Greentech Ltd, Plassim Infrastructure Ltd, Plassim Advanced Solutions in Sanitation Ltd, Hakohav Valves Industries Metal -1987 Ltd, Aqua Flowing Infrastructure Control Systems Ltd, Metzerplas Agriculture Cooperative Ltd, B. Gaon Retail & Trading Ltd, Gaon Agro - Rimon Management Services Ltd, B. Gaon Business -2004 Ltd, Gaon Antan Investments Ltd, Or Asaf Investments Ltd, Hamashbir Holdings -1999 Ltd, G.A.L Water Technologies Ltd, I.M.G. Retail Israel Ltd 以及 AHAVA Holdings LTD.这么多家公司的一名董事。
Guy Regev has over fteen years of experience in accounting, financial management and control and general management of commercial enterprises. He has served on Board of Directors since July 2011 and has served as a member of Audit Committee and Compensation Committee since February 2014. Mr. Regev has also been a director of OphthaliX since November 2011. Mr. Regev is currently the Chief Executive Officer of Gaon Holdings Ltd, a publicly traded Israeli holding company traded on the TASE which foces on three areas of operation Cleantech / Water, Financial Services, Retail/Trading. Mr. Regev is currently also the Chief Executive Officer of Middle East Tube Company Ltd a publicly traded Israeli company traded on the TASE which foces on steel pipe manufacturing and galvanization services. Mr. Regev was the Chief Executive Officer of Shaked Global Group Ltd, a privately held equity investment firm that provides value added capital to environmental related companies and technologies. Prior to joining Shaked, from 2001 to 2008, Mr. Regev was Vice President of Commercial Biness at Hoing& Construction Holding, or HCH, Israel's largest infrastructure company. His duties included being responsible for the consolidation and financial recovery of vario biness units within HCH. Prior to that, Mr. Regev carried several roles within the group including as a Chief Financial Officer and later the Chief Executive Officer of Blue Green Ltd., the environmental services subsidiary of HCH. Beten 1999 and 2001, Mr. Regev was a manager at Deloitte & Touche, Israel. Mr. Regev holds an LLB degree in Law (Israel) and is a licensed attorney and has been a licensed CPA since 1999. Mr. Regev is also a director of, The Green Way Ltd, Shtang Construction and Engineering Ltd, R.I.B.E. Consulting & Investment Ltd., Middle East Tube Company Ltd, Middle East Tube Indtries 2001 Ltd, Middle East Tubes Galvanizing (1994) Ltd, I Solar Greentech Ltd, Plassim Infrastructure Ltd, Plassim Advanced Solutions in Sanitation Ltd, Hakohav Valves Indtries Metal (1987) Ltd, Metzerplas Agriculture Cooperative Ltd, B. Gaon Retail & Trading Ltd, Gaon Agro Rimon Management Services Ltd, B. Gaon Biness (2004) Ltd, Gaon Antan Investments Ltd, Or Asaf Investments Ltd, Hamashbir Holdings (1999) Ltd, and AHAVA Holdings LTD. - Guy Regev在商业企业的会计，财务管理，主管部门和管理部门有超过12年的任职经历。他自2011年7月起一直在我们公司的董事会任职，并自2014年2月起，一直是我们公司审计委员会和薪酬委员会的成员。自2011年11月起，Regev先生还一直是OphthaliX的一名董事。Regev先生目前是Gaon Holdings Ltd.（一家以色列上市贸易公司，主要在自来水清洁，财务服务和零售贸易三个方面运营）的首席执行官。Regev先生目前还是Middle East Tube Company Ltd（一家以色列上市贸易公司，从事钢管制造和电镀服务）的首席执行官。另外，Regev先生还是Shaked Global Group Ltd（一家为环保关联和科技公司提供资本增值服务的私营股权公司，或称为Shaked公司）的首席执行官。2008年初，Regev先生加入了Shaked并在2014年4月离职。2011年11月以来，Regev先生还一直是OphthaliX公司的一名董事。在加入Shaked之前，2001年到2008年期间，Regev先生曾是HCH（以色列最大的基础设施公司）商业业务部的副主管。他在HCH公司的负责各个业务单元的巩固和财务复苏。在此之前，Regev先生曾在Blue-Green Ltd.（HCH的环境服务子公司）担任许多角色，包括首席财务官和之后的首席执行官。1999年到2001年期间，Regev先生曾是以色列Deloitte & Touche公司的经理。Regev先生拥有Law Israel的法学学士学位，是一位有证律师以及自1999年起成为一名注册会计师。Regev先生现在还是The Green Way Ltd, Shtang Construction 和Engineering Ltd, R.I.B.E. Consulting & Investment Ltd., Shaked Group Ltd, Aqua Investments Ltd, Middle East Tube Company Ltd, Middle East Tube - Industries 2001 Ltd, Middle East Tubes - Galvanizing -1994 Ltd, I-Solar Greentech Ltd, Plassim Infrastructure Ltd, Plassim Advanced Solutions in Sanitation Ltd, Hakohav Valves Industries Metal -1987 Ltd, Aqua Flowing Infrastructure Control Systems Ltd, Metzerplas Agriculture Cooperative Ltd, B. Gaon Retail & Trading Ltd, Gaon Agro - Rimon Management Services Ltd, B. Gaon Business -2004 Ltd, Gaon Antan Investments Ltd, Or Asaf Investments Ltd, Hamashbir Holdings -1999 Ltd, G.A.L Water Technologies Ltd, I.M.G. Retail Israel Ltd 以及 AHAVA Holdings LTD.这么多家公司的一名董事。
- Guy Regev has over fteen years of experience in accounting, financial management and control and general management of commercial enterprises. He has served on Board of Directors since July 2011 and has served as a member of Audit Committee and Compensation Committee since February 2014. Mr. Regev has also been a director of OphthaliX since November 2011. Mr. Regev is currently the Chief Executive Officer of Gaon Holdings Ltd, a publicly traded Israeli holding company traded on the TASE which foces on three areas of operation Cleantech / Water, Financial Services, Retail/Trading. Mr. Regev is currently also the Chief Executive Officer of Middle East Tube Company Ltd a publicly traded Israeli company traded on the TASE which foces on steel pipe manufacturing and galvanization services. Mr. Regev was the Chief Executive Officer of Shaked Global Group Ltd, a privately held equity investment firm that provides value added capital to environmental related companies and technologies. Prior to joining Shaked, from 2001 to 2008, Mr. Regev was Vice President of Commercial Biness at Hoing& Construction Holding, or HCH, Israel's largest infrastructure company. His duties included being responsible for the consolidation and financial recovery of vario biness units within HCH. Prior to that, Mr. Regev carried several roles within the group including as a Chief Financial Officer and later the Chief Executive Officer of Blue Green Ltd., the environmental services subsidiary of HCH. Beten 1999 and 2001, Mr. Regev was a manager at Deloitte & Touche, Israel. Mr. Regev holds an LLB degree in Law (Israel) and is a licensed attorney and has been a licensed CPA since 1999. Mr. Regev is also a director of, The Green Way Ltd, Shtang Construction and Engineering Ltd, R.I.B.E. Consulting & Investment Ltd., Middle East Tube Company Ltd, Middle East Tube Indtries 2001 Ltd, Middle East Tubes Galvanizing (1994) Ltd, I Solar Greentech Ltd, Plassim Infrastructure Ltd, Plassim Advanced Solutions in Sanitation Ltd, Hakohav Valves Indtries Metal (1987) Ltd, Metzerplas Agriculture Cooperative Ltd, B. Gaon Retail & Trading Ltd, Gaon Agro Rimon Management Services Ltd, B. Gaon Biness (2004) Ltd, Gaon Antan Investments Ltd, Or Asaf Investments Ltd, Hamashbir Holdings (1999) Ltd, and AHAVA Holdings LTD.
高管简历
中英对照 | 中文 | 英文- Sari Fishman
Sari Fishman曾担任我们的临床事务总监（从2004年到2014年）、业务发展总监（从2014年到2017年），并自2017年起担任业务发展副总裁。Fishman博士在以色列拉马特甘的巴伊兰大学（Bar-Ilan University）获得博士学位。
Sari Fishman has served as Director Clinical Affairs from 2004 to 2014, Director of Biness Development from 2014 to 2017 and since 2017 serves as VP of Biness Development. Dr. Fishman gained her Ph.D. at the Bar Ilan University, Ramat Gan, Israel. Dr. Sari Fishman is the daughter of Pnina Fishman, Chief Scientific Officer and the Chairman of Board of Directors.- Sari Fishman曾担任我们的临床事务总监（从2004年到2014年）、业务发展总监（从2014年到2017年），并自2017年起担任业务发展副总裁。Fishman博士在以色列拉马特甘的巴伊兰大学（Bar-Ilan University）获得博士学位。
- Sari Fishman has served as Director Clinical Affairs from 2004 to 2014, Director of Biness Development from 2014 to 2017 and since 2017 serves as VP of Biness Development. Dr. Fishman gained her Ph.D. at the Bar Ilan University, Ramat Gan, Israel. Dr. Sari Fishman is the daughter of Pnina Fishman, Chief Scientific Officer and the Chairman of Board of Directors.
- Motti Farbstein
Motti Farbstein，自2003年以来一直在Can-Fite工作。Farbstein先生在2003年8月至2005年5月期间担任我们的首席运营官，并从该日起担任首席运营和财务官。Farbstein先生还自2011年7月起担任Eye-Fite Ltd.的董事。Farbstein先生过去的管理经验包括担任Mor Research Application副总裁七年，该公司管理Clalit Health Services附属的所有医院和研究中心的知识产权商业化，Clalit Health Services是以色列最大的医疗保健提供商，也是以色列的第一家临床CRO。Farbstein先生在临床试验的数据管理方面也有丰富的经验。
Motti Farbstein has been with Can Fite since 2003. Mr. Farbstein has served as Chief Executive Officer since June 2023. Mr. Farbstein served as Chief Operating Officer from Augt 2003 until May 2005 and from that date onwards he served as Chief Operating and Financial Officer. Mr. Farbstein also serves as a director of Eye Fite Ltd. since July 2011. Mr. Farbstein's past managerial experience includes seven years as Vice President of Mor Research Application, a company that managed the commercialization of the intellectual property of all hospitals and research centers affiliated with Clalit Health Services, which is the largest healthcare provider in Israel and was Israel's first clinical CRO. Mr. Farbstein also has extensive experience in the data management of clinical trials.- Motti Farbstein，自2003年以来一直在Can-Fite工作。Farbstein先生在2003年8月至2005年5月期间担任我们的首席运营官，并从该日起担任首席运营和财务官。Farbstein先生还自2011年7月起担任Eye-Fite Ltd.的董事。Farbstein先生过去的管理经验包括担任Mor Research Application副总裁七年，该公司管理Clalit Health Services附属的所有医院和研究中心的知识产权商业化，Clalit Health Services是以色列最大的医疗保健提供商，也是以色列的第一家临床CRO。Farbstein先生在临床试验的数据管理方面也有丰富的经验。
- Motti Farbstein has been with Can Fite since 2003. Mr. Farbstein has served as Chief Executive Officer since June 2023. Mr. Farbstein served as Chief Operating Officer from Augt 2003 until May 2005 and from that date onwards he served as Chief Operating and Financial Officer. Mr. Farbstein also serves as a director of Eye Fite Ltd. since July 2011. Mr. Farbstein's past managerial experience includes seven years as Vice President of Mor Research Application, a company that managed the commercialization of the intellectual property of all hospitals and research centers affiliated with Clalit Health Services, which is the largest healthcare provider in Israel and was Israel's first clinical CRO. Mr. Farbstein also has extensive experience in the data management of clinical trials.